13.73
+1.18%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Stevanato Group SpA
Its shares trade under the ticker STVN. It has been listed since 16 July 2021. In the fiscal year to 31 December 2025, it reported revenue of €1.32bn and net income of €155.0m. At that date it held total assets of €2.93bn and shareholders' equity of €1.71bn.
Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The company is headquartered in Piombino Dese, Padova. The company went IPO on 2021-07-16. The firm delivers products, processes, and services across all stages of drug developments, including pre-clinical, clinical, and commercialization. Its Engineering segment includes the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology, and diagnostic manufacturing processes. The firm operates locally, in Europe, and globally, including Brazil, China, Mexico, and the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 16 Jul 2021
- Employees
- 6,010
- Website
- stevanatogroup.com ↗
- Head office
- PIOMBINO DESE (PD) VIA MOLINELLA, 17, PADUA, 35017
- Classification
- Surgical & Medical Instruments & Apparatus
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Marco LagoChief Financial Officer, since 2020
- Mr. Riccardo ButtaPresident, Americas
- Mr. Ugo GayChief Operations Officer
- Ms. Carla CostaChief Human Resources Officer
- Mr. Franco StevanatoExecutive Chairman of the Board, Chief Executive Officer, since 2010
- Mr. Sergio StevanatoEmeritus Chairman
- Ms. Michele MonicoPresident - DDS and IVD Business Unit, since 2025
- Mr. Raffaele PacePresident - Engineering Business Unit
- Mr. Mauro StocchiChief Business Officer
- Mr. Franco MoroDirector, since 2019
- Mr. Alvise SpinazziDirector
- Mr. Madhavan BalachandranIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Stevanato Group SpA employs 6010 employees in the Health Care sector.
- The company provides drug containment solutions for pharmaceutical industries globally.
- Engineering segment supports end-to-end manufacturing processes in Life Sciences Tools & Services.
Weaknesses
- The company has 5260 full-time employees as of 2021 IPO listing.
- Stevanato Group operates in Europe and the United States with limited presence in Asia.
- The firm's business is concentrated in the Life Sciences Tools & Services industry.
Opportunities
- Stevanato Group SpA has a presence in Brazil, China, and Mexico for global expansion.
- The company's Engineering segment offers services across all drug development stages.
- Global operations in Europe, the United States, and emerging markets present growth potential.
Threats
- The company faces competition in the Life Sciences Tools & Services industry.
- Stevanato Group SpA's operations are limited to specific regions like Europe and the United States.
- The firm's reliance on the pharmaceutical industry could pose risks during market downturns.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.